NCT02875548 (TRuST) is a Phase 1, PHASE2 clinical trial of Tazemetostat in Diffuse Large B-cell Lymphoma (DLBCL), sponsored by Epizyme, Inc..

Who is sponsoring NCT02875548?

NCT02875548 is sponsored by Epizyme, Inc..

What drugs are being tested in NCT02875548?

Interventions in NCT02875548: Tazemetostat.

What condition does NCT02875548 study?

NCT02875548 studies Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epitheliod Sarcoma (ES), Mesothelioma, Advanced Solid Tumors, Renal Medullary Carcinoma, Non-Hodgkin Lymphoma (NHL).

Is NCT02875548 still recruiting?

NCT02875548 is currently completed. Last updated 4 November 2025.

Last reviewed 2025-11-04 · How we verify

NCT02875548: TRuST

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study

Completed Phase 1, PHASE2 Last updated 4 November 2025

What this trial tests

Phase 1, PHASE2 trial testing Tazemetostat in Diffuse Large B-cell Lymphoma (DLBCL) in 58 participants. Completed in 26 September 2025.

Timeline

30 August 2016

Primary endpoint
26 September 2025

26 September 2025

Quick facts

Lead sponsor	Epizyme, Inc.
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	58
Start date	30 August 2016
Primary completion	26 September 2025
Estimated completion	26 September 2025
Sites	34 locations across France, Ukraine, Belgium, United Kingdom, Poland, Australia, United States

Drugs / interventions tested

Tazemetostat (tazemetostat) — full drug profile →

Conditions studied

Diffuse Large B-cell Lymphoma (DLBCL) — all drugs for Diffuse Large B-cell Lymphoma (DLBCL) →
Follicular Lymphoma (FL) — all drugs for Follicular Lymphoma (FL) →
Synovial Sarcoma — all drugs for Synovial Sarcoma →
Epitheliod Sarcoma (ES) — all drugs for Epitheliod Sarcoma (ES) →

Sponsor

Epizyme, Inc. — full company profile →

Who can join

18 and older, any sex, with Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will provide continuing availability to tazemetostat for people that have previously completed participation in a tazemetostat study, either with monotherapy (single drug treatment) or combination therapy. The aim of the study will be to assess the long-term safety of tezemetostat.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.
Cheng Y, He C, Wang M, Ma X, et al · · 2019 · cited 760× · PMID 31871779 · DOI 10.1038/s41392-019-0095-0
The SWI/SNF complex in cancer - biology, biomarkers and therapy.
Mittal P, Roberts CWM. · · 2020 · cited 537× · PMID 32303701 · DOI 10.1038/s41571-020-0357-3
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.
Morschhauser F, Tilly H, Chaidos A, McKay P, et al · · 2020 · cited 448× · PMID 33035457 · DOI 10.1016/s1470-2045(20)30441-1
Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity.
Wainwright EN, Scaffidi P. · · 2017 · cited 250× · PMID 28718414 · DOI 10.1016/j.trecan.2017.04.004
EZH2-Targeted Therapies in Cancer: Hype or a Reality.
Eich ML, Athar M, Ferguson JE, Varambally S. · · 2020 · cited 188× · PMID 32978169 · DOI 10.1158/0008-5472.can-20-2147
Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease.
Bhat KP, Ümit Kaniskan H, Jin J, Gozani O. · · 2021 · cited 181× · PMID 33469207 · DOI 10.1038/s41573-020-00108-x
The epigenomics of sarcoma.
Nacev BA, Jones KB, Intlekofer AM, Yu JSE, et al · · 2020 · cited 166× · PMID 32782366 · DOI 10.1038/s41568-020-0288-4
Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends.
Nepali K, Liou JP. · · 2021 · cited 122× · PMID 33840388 · DOI 10.1186/s12929-021-00721-x

Verify or expand the search:

Other trials of Tazemetostat

Trials testing the same drug.

NCT06575686 — Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma · Phase 2 · suspended
NCT06692452 — Tazemetostat Plus CHOP in 1L T-cell Lymphoma · Phase 2 · withdrawn
NCT06242834 — Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggres · Phase 2 · active not recruiting
NCT05983965 — Study of Tazemetostat in Lymphoid Malignancies · Phase 1 · terminated
NCT05151588 — Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma · Phase 2 · not yet recruiting

Other recruiting trials for Diffuse Large B-cell Lymphoma (DLBCL)

Currently open trials in the same condition.

NCT06832228 — Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL · NA · recruiting
NCT06091865 — A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined · Phase 3 · active not recruiting
NCT07473167 — Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients · Phase 1, PHASE2 · recruiting
NCT05583149 — Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas · Phase 2 · active not recruiting
NCT03936153 — Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell L · Phase 2 · recruiting

Other Epizyme, Inc. trials

Trials by the same sponsor.

NCT06068881 — A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lym · Phase 2 · withdrawn
NCT05121103 — A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With R · Phase 1 · terminated
NCT05205252 — A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer. · Phase 1, PHASE2 · withdrawn
NCT04762160 — SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicula · Phase 2 · terminated
NCT04224493 — A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenal · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02875548 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Epizyme, Inc.
Last refreshed: 4 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02875548.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing